Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioMark Diagnostics
Richmond, British Columbia, Canadabiomarkdiagnostics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
BioMark’s lead liquid biopsy test for early-stage lung cancer demonstrated high specificity and accuracy in a large clinical study. The test achieved AUROC values over 93% for distinguishing stage I-II non-small cell lung cancer from controls—including patients with non-cancerous lung diseases—confirming the robustness of their metabolomic/machine learning approach. This positions the technology as a promising tool for early diagnosis and management of lung cancer
- Therapeutic areas
- Oncology
- Modalities
- Liquid biopsyDiagnostic assayMetabolomics-based diagnostics
- Industry
- Metabolite Diagnostics
Beyond the preview
Go deeper on BioMark Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMark Diagnostics.